SCHEMBL12436902

SCHEMBL12436902

CC(=O)NCC1(C(C)=O)CCOCC1

nearest known ligand 0.43

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 1/20 0.33
OPRL1 P41146 1/20 0.33
NPSR1 Q6W5P4 1/20 0.32
ALDH1A1 P00352 3/20 0.32
HTT P42858 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
TSHR P16473 1/20 0.31
CASP1 P29466 1/20 0.31
KDM4E B2RXH2 1/20 0.31
MAPK1 P28482 1/20 0.31
HIF1A Q16665 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
TP53 P04637 1/20 0.30
GAA P10253 1/20 0.30
P2RX7 Q99572 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25543888 0.86 NPSR1 (0.38) OPRM1OPRL1NPSR1ALDH1A1TSHR
SCHEMBL12436906 0.84 TSHR (0.35) ALDH1A1TSHRL3MBTL1P2RX7
SCHEMBL21937426 0.82 ALDH1A1 (0.31) OPRM1OPRL1ALDH1A1HTTMAPK1
SCHEMBL12436899 0.79 HCRTR2 (0.44) ALDH1A1TDP1TSHRL3MBTL1GAA
SCHEMBL15461409 0.78 OPRM1 (0.46) OPRM1OPRL1NPSR1ALDH1A1HTT
SCHEMBL15461398 0.78 NPSR1 (0.33) OPRM1OPRL1NPSR1ALDH1A1HTT
SCHEMBL15461401 0.77 ALDH1A1 (0.34) OPRM1OPRL1NPSR1ALDH1A1HTT
SCHEMBL12436903 0.76 ALDH1A1 (0.57) NPSR1ALDH1A1HTTKDM4EMAPK1
SCHEMBL15461399 0.76 CNR2 (0.34) OPRM1OPRL1NPSR1ALDH1A1HTT
SCHEMBL13804310 0.75 SMN1; SMN2 (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE49686-E1 Nitrogen-containing heterocyclic compound and use of same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-10-10 US disclosed
US-RE49686-E1 Nitrogen-containing heterocyclic compound and use of same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-10-10 US disclosed
US-RE48334-E1 Nitrogen-containing heterocyclic compound and use of same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2020-12-01 US disclosed
US-20110178060-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME TAKEDA PHARMACEUTICAL COMPANY LIMITED 2011-07-21 US disclosed
US-20110178060-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME TAKEDA PHARMACEUTICAL COMPANY LIMITED 2011-07-21 US disclosed
WO-2010032856-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME 武田薬品工業株式会社 (JP) 2010-03-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178060-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME NTSR2, BDKRB1, AVPR1B OPRM1 108/4885OPRL1 18/4885NPSR1 20/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.